Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ciphergen Biosystems(CIPH): -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (215)	3/24/2004 1:23:45 PM
From: tuck	Read Replies (1) \| Respond to of 510

>>Biochem Biophys Res Commun. 2004 Apr 9;316(3):918-23. Proteomic identification of biomarkers expressed by human pluripotent stem cells. Hayman MW, Przyborski SA. School of Biological and Biomedical Science, University of Durham, South Road, Durham DH1 3LE, UK. The ability to effectively monitor the behaviour of pluripotent stem cells and their differentiation is key to their use in basic and clinical research. Molecules expressed in particular cell types can be used to report the status of cell differentiation and is a recognised means of assessing the behaviour of cell cultures. There are currently few useful markers of stem cells and there is no rapid way to accurately determine their level of expression. In this study, we describe for the first time the potential of surface enhanced laser desorption/ionisation time-of-flight mass spectrometry (SELDI-TOF-MS) to identify novel biomarkers of human pluripotent embryonal carcinoma stem cells and their differentiated derivatives. This approach allows the rapid and sensitive screening of cell samples without the need to purify the specimen prior to analysis. The identification of proteins expressed in specific cell populations will provide valuable tools for monitoring cellular development.<< I should note tht there was another abstract, by a Dutch group concerning reproducibility. Though it also mentions MALDI MS as having some of the same issues: aacr04.agora.com Basically a matter of mass accuracy being much better than mass intensity accuracy. So we still know what, but not how much. But there was also a comparison to Luminex' Xmap system, in which it seemed SELDI did better: aacr04.agora.com Cheers, Tuck

To: tuck who wrote (215)	4/2/2004 1:01:49 AM
From: mopgcw	Read Replies (1) \| Respond to of 510

Piper wrap-up on AACR indicated that them meeting was dominated again by Biomarkers and pharmacogenomic markers. They also noted that they believe bimarker research to remain an important driver for the mass spec mrkt and view ciph to be the pure play in the space. They are comfy with their $81.5mm rev est for the year and note the hiring of 5 program managers/hiring in europe and buy-out of their Japan sales force. system demos are up significantly and appear to have been successful winning several lost 4q03 system placements. fwiw. regards, george